Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected

Danuta M. Skowronski, Gaston De Serres, David Scheifele, Margaret L. Russell, Richard Warrington, Herbert Dele Davies, Marc Dionne, Bernard Duval, James Kellner, Judy MacDonald

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

During the 2000-2001 influenza immunization campaign in Canada, an oculorespiratory syndrome (ORS) was recognized as adverse event associated with one of the vaccines administered. The initial surveillance case definition for ORS in 2000-2001 specified onset within 24 h after vaccination and resolution within 48 h after onset; the restriction on the duration of ORS was removed from the case definition for the vaccine distributed during the 2001-2002 influenza season. The implicated vaccine contained large aggregates of unsplit virions; alterations to the manufacturing process for the vaccine distributed during 2001-2002 addressed this. A randomized, double-blind, placebo-controlled trial assessed the safety of the reformulated version in previously affected adults. The trial was halted early, after 61 participants had received an injection (34 had received vaccine, and 27 had received placebo). The vaccine-attributable recurrence rate for onset of ORS within 24 h after injection was 33% (95% confidence interval [CI], 10%-53%); for cases that resolved within 48 h, this rate was 27% (95% CI, 5%-47%). Previously affected persons should be informed of the risk of ORS recurrence but also that episodes of such recurrence are mild and well tolerated.

Original languageEnglish (US)
Pages (from-to)1059-1066
Number of pages8
JournalClinical Infectious Diseases
Volume37
Issue number8
DOIs
StatePublished - Oct 15 2003
Externally publishedYes

Fingerprint

Human Influenza
Vaccination
Vaccines
Placebos
Recurrence
Confidence Intervals
Injections
Virion
Canada
Immunization
Safety

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected. / Skowronski, Danuta M.; De Serres, Gaston; Scheifele, David; Russell, Margaret L.; Warrington, Richard; Davies, Herbert Dele; Dionne, Marc; Duval, Bernard; Kellner, James; MacDonald, Judy.

In: Clinical Infectious Diseases, Vol. 37, No. 8, 15.10.2003, p. 1059-1066.

Research output: Contribution to journalArticle

Skowronski, Danuta M. ; De Serres, Gaston ; Scheifele, David ; Russell, Margaret L. ; Warrington, Richard ; Davies, Herbert Dele ; Dionne, Marc ; Duval, Bernard ; Kellner, James ; MacDonald, Judy. / Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected. In: Clinical Infectious Diseases. 2003 ; Vol. 37, No. 8. pp. 1059-1066.
@article{b51f34e267cb4d6e9ec7b1e94e5fa956,
title = "Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected",
abstract = "During the 2000-2001 influenza immunization campaign in Canada, an oculorespiratory syndrome (ORS) was recognized as adverse event associated with one of the vaccines administered. The initial surveillance case definition for ORS in 2000-2001 specified onset within 24 h after vaccination and resolution within 48 h after onset; the restriction on the duration of ORS was removed from the case definition for the vaccine distributed during the 2001-2002 influenza season. The implicated vaccine contained large aggregates of unsplit virions; alterations to the manufacturing process for the vaccine distributed during 2001-2002 addressed this. A randomized, double-blind, placebo-controlled trial assessed the safety of the reformulated version in previously affected adults. The trial was halted early, after 61 participants had received an injection (34 had received vaccine, and 27 had received placebo). The vaccine-attributable recurrence rate for onset of ORS within 24 h after injection was 33{\%} (95{\%} confidence interval [CI], 10{\%}-53{\%}); for cases that resolved within 48 h, this rate was 27{\%} (95{\%} CI, 5{\%}-47{\%}). Previously affected persons should be informed of the risk of ORS recurrence but also that episodes of such recurrence are mild and well tolerated.",
author = "Skowronski, {Danuta M.} and {De Serres}, Gaston and David Scheifele and Russell, {Margaret L.} and Richard Warrington and Davies, {Herbert Dele} and Marc Dionne and Bernard Duval and James Kellner and Judy MacDonald",
year = "2003",
month = "10",
day = "15",
doi = "10.1086/378274",
language = "English (US)",
volume = "37",
pages = "1059--1066",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected

AU - Skowronski, Danuta M.

AU - De Serres, Gaston

AU - Scheifele, David

AU - Russell, Margaret L.

AU - Warrington, Richard

AU - Davies, Herbert Dele

AU - Dionne, Marc

AU - Duval, Bernard

AU - Kellner, James

AU - MacDonald, Judy

PY - 2003/10/15

Y1 - 2003/10/15

N2 - During the 2000-2001 influenza immunization campaign in Canada, an oculorespiratory syndrome (ORS) was recognized as adverse event associated with one of the vaccines administered. The initial surveillance case definition for ORS in 2000-2001 specified onset within 24 h after vaccination and resolution within 48 h after onset; the restriction on the duration of ORS was removed from the case definition for the vaccine distributed during the 2001-2002 influenza season. The implicated vaccine contained large aggregates of unsplit virions; alterations to the manufacturing process for the vaccine distributed during 2001-2002 addressed this. A randomized, double-blind, placebo-controlled trial assessed the safety of the reformulated version in previously affected adults. The trial was halted early, after 61 participants had received an injection (34 had received vaccine, and 27 had received placebo). The vaccine-attributable recurrence rate for onset of ORS within 24 h after injection was 33% (95% confidence interval [CI], 10%-53%); for cases that resolved within 48 h, this rate was 27% (95% CI, 5%-47%). Previously affected persons should be informed of the risk of ORS recurrence but also that episodes of such recurrence are mild and well tolerated.

AB - During the 2000-2001 influenza immunization campaign in Canada, an oculorespiratory syndrome (ORS) was recognized as adverse event associated with one of the vaccines administered. The initial surveillance case definition for ORS in 2000-2001 specified onset within 24 h after vaccination and resolution within 48 h after onset; the restriction on the duration of ORS was removed from the case definition for the vaccine distributed during the 2001-2002 influenza season. The implicated vaccine contained large aggregates of unsplit virions; alterations to the manufacturing process for the vaccine distributed during 2001-2002 addressed this. A randomized, double-blind, placebo-controlled trial assessed the safety of the reformulated version in previously affected adults. The trial was halted early, after 61 participants had received an injection (34 had received vaccine, and 27 had received placebo). The vaccine-attributable recurrence rate for onset of ORS within 24 h after injection was 33% (95% confidence interval [CI], 10%-53%); for cases that resolved within 48 h, this rate was 27% (95% CI, 5%-47%). Previously affected persons should be informed of the risk of ORS recurrence but also that episodes of such recurrence are mild and well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0142218465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142218465&partnerID=8YFLogxK

U2 - 10.1086/378274

DO - 10.1086/378274

M3 - Article

VL - 37

SP - 1059

EP - 1066

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -